ReviewFrontiers in psychiatry2026
Therapeutic potential of propranolol in central nervous system disorders.
Review in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Propranolol (Prop), a classic non-selective β-adrenergic receptor antagonist, has long played a significant role in the treatment of cardiovascular diseases such as hypertension and arrhythmias. Compared with its peripheral regulatory effects, the potential therapeutic value of Prop in neurological disorders such as post-traumatic stress disorder (PTSD), memory dysfunction, autism spectrum disorder (ASD), anxiety, migraine prophylaxis, and essential tremor is gradually being re-evaluated. Methods: This review aims to integrate the latest evidence from clinical and preclinical studies, systematically reviewing the effects of Prop on neurological diseases and its potential mechanisms. Results: Specifically, we explore its translational value from the perspective of β-adrenergic receptor subtype-specific regulation, thereby assessing its potential for precision medicine in neurology. Discussion: Finally, this review outlines novel therapeutic strategies targeting β receptors for treating central nervous system (CNS) diseases, with the ultimate goal of providing a robust theoretical foundation and clear translational pathways for future drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.